Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AT2391: Phase I data

In an ongoing, open-label, U.S. Phase I trial,

Read the full 88 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE